Uncategorized

Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data

Published

on

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version